The search for a vaccine for the COVID-19 strain of coronavirus has put the spotlight once again on the innovative pharmaceuticals sector. As pharmaceutical companies and innovators across the globe work diligently on a vaccine, many of these companies may be looking to protect their innovation. While patents have many benefits, in the face of a global health emergency, there are some key factors innovators should consider.
Timeline for Patent Registration
Patents can provide broad protection for invention and innovation. They can also create a significant advantage in the marketplace. However, patent registration takes time and may require significant resources. According to the United States Patent and Trademark Office (USPTO), on average, it takes approximately 22 months to get patent approval. This period may be shortened by taking advantage of one of the USPTO’s accelerated examination procedures and may be shortened by utilizing the USPTO prioritized examination option, where a final decision on patentability is made within 12 months from the filing date of the patent application. …
Continue Reading The Race for a COVID-19 Vaccine is On: Key Factors May Impact Patent Protection
David J. Dykeman authored an article titled “5 Tips to Protect Your Medtech Startup’s Innovations.” The article was published in Medical Design & Outsourcing as well as MassDevice.
The TV franchise Star Trek featured some amazing technological advancements that have continued to intrigue us for many years. For example, the “replicator” was a device that was able to…
Continue Reading Could Star Trek’s Replicator Become a Reality with 3D Printing Technology?
As companies continue to implement mobile health apps, aggregate clinical trial results, and isolate disease through computer modeling, they are also focused on possible risks. Harnessing cloud technology gives rise to a constant concern about keeping sensitive data secure.
Medicine has led the drive for nimble handling and accessibility of information. Electronic health records and clinical decision support have been widely adopted. Physician order entry facilitates scrutiny of outcomes. Stats can be compared thanks to industry standards for sharing. Devices for patient compliance and fitness provide value by accumulating user information to assess individual results and detect trends. Finally, better processing power can employ sophisticated algorithms to sift hundreds of millions of compounds and billions of DNA base pairs in a quest to discover drug targets.
Israel is a garden of inventiveness and Israelis have a strong tradition of contributing to technology and life sciences. Breathing the innovation when I lived there, I was privileged to test PrimeSense’s 3D camera, help bring Notal Vision’s tool to gauge macular degeneration to the United States, deliver a turn-key VoIP network in Nigeria and Zambia on behalf of VocalTec, license ecommerce and security software to dozens of Fortune 100 companies, watch knee surgery with miraculous tissue-repairing Regentis hydrogel, play with a gear box created from an Objet (now Stratasys) 3D printer, and negotiate sponsored research, patent licenses and clinical trials on behalf of emerging pharmaceutical companies.
Figuring out what gives rise to the “start-up nation” character, with wildly disproportionate foreign direct investment and numbers of translated books, cited academics, filed patents, Nasdaq companies, successful exits, and tuneful children’s songs, is a pervasive new-age question. Many answers have been floated, including its world-class research institutions, the very first technology transfer offices for commercialization of academic R&D, raw skills honed in one of the best-trained and most-sophisticated militaries, a culture of questioning, and a flood of ex-Soviet engineering talent over three decades. Naturally one can’t discount that there are real issues to be addressed too. Israelis have done it — from discerning security risks through synthesis of big data to making the desert bloom with fruit, vegetables, fish, and minerals.…
Continue Reading Ingenuity in Israel’s Water
Emerging medical device companies should consider these points when weighing a potential merger, strategic partnership or investment:
1. Identify unmet medical needs
Medical device titans are actively looking to acquire new technologies to treat unmet medical needs and drive market adoption. Larger medtech companies often view early-stage companies as outsourced R&D labs, and will pay a premium price for products that can drive future revenue. The larger the potential market, the higher the value to medtech titans.
2. Know the market and competitors
Acquiring technologies that can transform or dominate a market drives many deals and collaborations. Disruptive technologies that improve patient outcomes are in high demand. Larger medtech companies are always on the lookout for new devices or improved treatments that have no or few competitors. Understanding the strategic investment goals and criteria of potential suitors will further refine and focus a growing medtech company’s efforts to gain visibility and generate productive relationships.…
Continue Reading M&A, Investment or Partnering Checklist for Medtech Companies
On Oct. 23, 2014, Greenberg Traurig’s Life Sciences & Medical Technology Group hosted its inaugural MedTech Partnering Day from 8:30 a.m. – 2 p.m. at the firm’s Boston office.…
Continue Reading Greenberg Traurig Hosts MedTech Partnering Day